Drugsupdate.com is up for sale. To own one of the most recognized online brands by doctors in India with millions of visitors - click here.

logo image

Nimotuzumab information from DrugsUpdate  

See Available Brands of Nimotuzumab in India

Nimotuzumab, a humanized monoclonal antibody, is prescribed for the treatment of glioma in adults and children.


Nimotuzumab is a highly-selective epidermal growth factor (EGF) receptor antagonist that binds with EGF ligands. EGF is important for angiogenesis, cellular proliferation, apoptosis and cell motility in malignant cells.


Nimotuzumab is administered as a combined therapy with chemotherapy or radiotherapy. After infusion, the AUC and Cmax increase rapidly depending on the dose range. The biologic is distributed mainly in bladder, liver, spleen, heart and kidneys. The plasma clearance rate is influenced by renal clearance rate. Nimotuzumab is mostly excreted via the urine.

Nimotuzumab Indications / Nimotuzumab Uses

No information available

Nimotuzumab Adverse Reactions / Nimotuzumab Side Effects

Nimotuzumab can cause myalgia, chills, fatigue, nausea, pyrexia, tremors, erythema, somnolence, disorientation, leucopenia, fatigue, hematuria and elevated LFTs. Rarely, Nimotuzumab can cause severe hypotension and urticaria.


Caution should be exercised before administration of Nimotuzumab to patients who were previously treated with murine monoclonal antibody, individuals with Theracim hypersensitivity, diabetes mellitus patients, cardiac dysfunction and arterial hypertension.

Special Precautions

No information available

Other Drug Interactions

Nimotuzumab may interact with EGFR inhibitors, gemcitabine and irinotecan.

Other Interactions

No information available


Consider administration of 200 mg of Nimotuzumab as a combined therapy with radiation treatment (2 Gy) daily. The dosage can be prescribed for 5 days/week and the cumulative radiation dose should not exceed 50-60 Gy for six weeks.

Adolescents and children:
Consider administration of 150 mg/m2 BSA weekly as a monotherapy for six weeks. In case of positive clinical response, the maintenance dose of 150 mg/m2 BSA, every three weeks can be prescribed until the development of tolerance or worsening of disease.


No information available

List of Contraindications

Nimotuzumab and Pregnancy

No adequate clinical studies to assess the safety of Nimotuzumab during pregnancy. Do not prescribe Nimotuzumab to pregnant women.

Nimotuzumab and Lactation

Nimotuzumab can pass through the breast milk and harm a nursing infant. Do not take Nimotuzumab while breastfeeding a baby.

Nimotuzumab and Children

The dosage and duration of Nimotuzumab should be as prescribed by a medical oncologist.

Nimotuzumab and Geriatic

No information available

Nimotuzumab and Other Contraindications

No information available


Store at 2-8°C

Lab interference

Store at 2-8°C

© 2011-2019 DrugsUpdate.com. Disclaimer | Site Map

  • Companies that own platforms will own the market
  • Trusted and recognized by all Doctors
  • Access to Millions of Visitors instantly.
  • Companies that own platforms will own the market
  • Trusted and recognized by all Doctors
  • Access to Millions of Visitors instantly.